scPharmaceuticals Stock (NASDAQ:SCPH)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$3.31

52W Range

$3.08 - $6.71

50D Avg

$3.84

200D Avg

$4.46

Market Cap

$169.64M

Avg Vol (3M)

$394.86K

Beta

0.14

Div Yield

SCPH Company Profile

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

135

IPO Date

Nov 17, 2017

Website

SCPH Performance

SCPH Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$13.59M	-	-
Operating Income	$-55.40M	$-36.16M	$-25.82M
Net Income	$-54.81M	$-37.52M	$-30.49M
EBITDA	$-54.77M	$-33.54M	$-25.46M
Basic EPS	$-1.42	$-1.32	$-1.11
Diluted EPS	$-1.42	$-1.32	$-1.11

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 13, 24 | 7:05 PM

Q2 24Aug 15, 24 | 5:10 AM

Q1 24May 14, 24 | 12:00 AM

Peer Comparison

Ticker	Company
CNTA	Centessa Pharmaceuticals plc
KTTA	Pasithea Therapeutics Corp.
MCRB	Seres Therapeutics, Inc.
MNPR	Monopar Therapeutics Inc.
IOVA	Iovance Biotherapeutics, Inc.
ONCY	Oncolytics Biotech Inc.
DMAC	DiaMedica Therapeutics Inc.
MIST	Milestone Pharmaceuticals Inc.
LYRA	Lyra Therapeutics, Inc.